Protagonist Therapeutics

Protagonist Therapeutics PTGX Stock

$121.40   -2.112559%
Add to favorites
Market Cap
$7.92B
LOW - HIGH [24H]
$120.15 - $125.74
VOLUME [24H]
$600.73K
P/E Ratio
25.66
Earnings per share
$4.73
ISIN
US74366E1029
Price   Prediction

Protagonist Therapeutics Price Chart

Sorry, that's all we've gotfor now...

Protagonist Therapeutics (PTGX) stock price today is 121.4 USD on Tech Market Middle (-2.11% on the day). Updated .

Protagonist Therapeutics PTGX Financial and Trading Overview

Protagonist Therapeutics stock price 121.4 USD
Previous Close 124.02 USD
Open 123.41 USD
Bid 97.79 USD x 200
Ask 175.12 USD x 200
Day's Range 120.15 - 125.74 USD
52 Week Range 77 - 160.81 USD
Volume 600.73K USD
Avg. Volume 665.36K USD
Market Cap 7.92B USD
Beta (5Y Monthly) 1.217
PE Ratio (TTM) 25.665962
EPS (TTM) 4.73 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date N/A
1y Target Est 182.36 USD

PTGX Valuation Measures

Enterprise Value 7.3B USD
Trailing P/E 25.665962
Forward P/E 348.79044
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 14.3627615
Price/Book (mrq) 7.2974277
Enterprise Value/Revenue 13.238
Enterprise Value/EBITDA 22.494

Trading Information

Protagonist Therapeutics Stock Price History

Beta (5Y Monthly) 1.217
52-Week Change 45.22%
S&P500 52-Week Change 8.67%
52 Week High 160.81 USD
52 Week Low 77 USD
50-Day Moving Average 138.68 USD
200-Day Moving Average 120.13 USD

PTGX Share Statistics

Avg. Volume (3 month) 665.36K USD
Avg. Daily Volume (10-Days) 587.9K USD
Shares Outstanding 65.27M
Float 53.36M
Short Ratio 13.75
% Held by Insiders 0.69%
% Held by Institutions 121.20%
Shares Short 10.24M
Short % of Float 18.23%
Short % of Shares Outstanding 15.70%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin 62.03%
Operating Margin (ttm) 58.56%
Gross Margin 99.80%
EBITDA Margin 58.85%

Management Effectiveness

Return on Assets (ttm) 21.85%
Return on Equity (ttm) 39.56%

Income Statement

Revenue (ttm) 551.69M USD
Revenue Per Share (ttm) 8.44 USD
Quarterly Revenue Growth (yoy) 5723.59%
Gross Profit (ttm) 550.59M USD
EBITDA 324.68M USD
Net Income Avi to Common (ttm) 342.26M USD
Diluted EPS (ttm) 4.73
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 800.06M USD
Total Cash Per Share (mrq) 12.26 USD
Total Debt (mrq) 8.63M USD
Total Debt/Equity (mrq) 0.8 USD
Current Ratio (mrq) 19.852
Book Value Per Share (mrq) 16.636

Cash Flow Statement

Operating Cash Flow (ttm) 109.91M USD
Levered Free Cash Flow (ttm) -24011624 USD

Profile of Protagonist Therapeutics

Country United States
State CA
City Newark
Address 7707 Gateway Boulevard
ZIP 94560
Phone 510 474 0170
Website https://www.protagonist-inc.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 149

Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Q&A For Protagonist Therapeutics Stock

What is a current PTGX stock price?

Protagonist Therapeutics PTGX stock price today per share is 121.4 USD.

How to purchase Protagonist Therapeutics stock?

You can buy PTGX shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Protagonist Therapeutics?

The stock symbol or ticker of Protagonist Therapeutics is PTGX.

Which industry does the Protagonist Therapeutics company belong to?

The Protagonist Therapeutics industry is Biotechnology.

How many shares does Protagonist Therapeutics have in circulation?

The max supply of Protagonist Therapeutics shares is 65.27M.

What is Protagonist Therapeutics Price to Earnings Ratio (PE Ratio)?

Protagonist Therapeutics PE Ratio is 25.66596200 now.

What was Protagonist Therapeutics earnings per share over the trailing 12 months (TTM)?

Protagonist Therapeutics EPS is 4.73 USD over the trailing 12 months.

Which sector does the Protagonist Therapeutics company belong to?

The Protagonist Therapeutics sector is Healthcare.

Protagonist Therapeutics PTGX included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
us US Tech Composite IXIC US 22617.73 USD —
-5.28
10.6B USD — 22513.01 USD — 23837.76 USD — — 10.6B USD —
us Stlmt ID US Tech Biotechnology NBX US 4000.62 USD —
-1.26
— — 3927.42 USD — 4148.65 USD — — — —
us US Tech Global Market Composite NQGM US 1743.91 USD —
-3.66
— — 1738.23 USD — 1808.43 USD — — — —
us US Tech Biotechnology NBI US 6781.89 USD —
-1.73
— — 6767.31 USD — 6980.47 USD — — — —
us US Tech Health Care IXHC US 1282.67 USD —
-1.79
— — 1279.99 USD — 1317.94 USD — — — —
$2.09T
Total marketcap
$110.7B
Total volume
BTC 57.95%   •   ETH 9.84%
Dominance
Select currency